ELEVIDYS (delandistrogene moxeparvovec-rokl)

Office-Administration – intravenous infusion

Diagnosis considered for coverage:
  • Duchenne Muscular Dystrophy (DMD): Indicated for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. 
    • This indication is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin observed in patients treated with Elevidys. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Coverage Criteria:

For diagnosis of Duchenne muscular dystrophy (DMD):

  • Diagnosis of Duchenne muscular dystrophy (DMD); AND
  • Mutation in the DMD gene has been confirmed; AND
  • No deletion in exon 8 or exon 9 in the DMD gene is present; AND
  • Patient is 4 or 5 years of age; AND
  • Patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.); AND
  • Anti-AAVrh74 total binding antibody titers are less than 1:400; AND
  • Patient will receive a corticosteroid regimen prior to and following the administration of Elevidys in line with the FDA-approved recommendations in the labeling; AND
  • Provider attests that all of the following laboratory values have been checked prior to therapy and will be monitored after administration according to the FDA-approved recommendations in the labeling:
    • Liver function (i.e., clinical exam, GGT, total bilirubin) 
    • Platelet counts 
    • Troponin-I; AND
  • Patient does not have clinical signs or symptoms of infection; AND
  • Patient will not receive exon-skipping therapies for DMD [e.g., Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), Vyondys 53 (golodirsen)] concomitantly or following Elevidys treatment; AND
  • Prescribed by or in consultation with a neurologist who has experience treating children; AND
  • Patient has never received Elevidys treatment in their lifetime.
Dosing:

DMD:

  • The recommended dose of ELEVIDYS is 1.33 × 1014 vector genomes per kilogram (vg/kg) of body weight (or 10 mL/kg body weight)
    • ELEVIDYS dose (in mL) = patient body weight (in kilogram) x 10
    • Number of ELEVIDYS vials needed = ELEVIDYS dose (in mL) divided by 10 (round to the nearest number of vials)
Coverage Duration: 
  • One (1) Time Authorization in Lifetime
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • DMD is the most common pediatric muscular dystrophy, with an incidence of around 400 to 600 cases per year and a prevalence of approximately 9,000 to 12,000 males in the United States (U.S.) (ICER 2019, Klimchak 2023). The estimated incidence worldwide is 1 in 3,500 to 5,000 live male births (Mendell et al 2013).
  • Elevidys is a recombinant adeno-associated viral serotype rh74 (AAVrh74)-based gene therapy designed to deliver a copy of the gene encoding a micro-dystrophin protein expressed in normal muscle cells.
  • Elevidys is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.
Policy Updates:
  • 03/01/2024 – New policy approved by WHA P&T Committee. (P&T, 02/20/2024)
References:
  • Elevidys Prescribing Information. Sarepta Therapeutics, Inc. Cambridge, MA. June 2023. 

Last review date: March 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone